Description
Orsema 0.50 mg is a semaglutide-based injectable medication developed by Incepta Pharmaceuticals Ltd., designed to manage type 2 diabetes mellitus and assist in weight management. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner, aiding in blood sugar regulation. Additionally, it slows gastric emptying and reduces appetite, contributing to weight loss. Administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm, Orsema 0.50 mg serves as a maintenance dose following an initial 0.25 mg dose. Common side effects include nausea, vomiting, diarrhea, and abdominal discomfort, while serious risks encompass pancreatitis and diabetic retinopathy complications. Orsema is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Proper storage involves refrigeration between 2°C and 8°C, avoiding freezing. This medication is available in Bangladesh and should be used under medical supervision as part of a comprehensive diabetes management plan.
 100 IU 3 ML.webp)
.jpg)
.jpeg)
.jpg)
.webp)
.jpg)
.jpg)
.jpeg)
.webp)
.jpg)
.jpg)
.jpeg)
.png)
.jpeg)
.webp)
 400MG.jpg)
.jpg)
.jpg)
Change Language